Tandutinib Inhibits the Akt/mTOR Signaling Pathway to Inhibit Colon Cancer Growth

Sivapriya Ponnurangam1, David Standing1, Parthasarathy Rangarajan1, and Dharmalingam Subramaniam1,2

Abstract

The c-Kit receptor can activate distinct signaling pathways including phosphoinositide 3-kinase (PI3K)/Akt and mTOR. Aberrant c-Kit activation protects cells from apoptosis and enhances invasion of colon carcinoma cells. Tandutinib is a novel quinazoline-based inhibitor of the type III receptor tyrosine kinases including c-Kit. We determined the effect of tandutinib on colon cancer growth and identified a mechanism of action. Tandutinib inhibited phosphorylation of c-Kit, Akt, mTOR, and p70S6 kinase. In addition, tandutinib significantly inhibited the proliferation and colony formation ability of colon cancer cell lines but did not affect normal colonic epithelial cells. There were increased levels of activated caspase-3 and Bax/Bcl2 ratio, coupled with a reduction in cyclin D1, suggesting apoptosis. There was also a downregulation of COX-2, VEGF, and interleukin-8 expression, suggesting effects on cancer-promoting genes. In addition, overexpressing constitutively active Akt partially suppressed tandutinib-mediated colon cancer cell growth. In vivo, intraperitoneal administration of tandutinib significantly suppressed growth of colon cancer tumor xenografts. There was a reduction in CD31-positive blood vessels, suggesting that there was an effect on angiogenesis. Tandutinib treatment also inhibited the expression of cancer-promoting genes COX-2 and VEGF and suppressed the activation of Akt/mTOR signaling proteins in the xenograft tissues. Together, these data suggest that tandutinib is a novel potent therapeutic agent that can target the Akt/mTOR/p70S6K signaling pathway to inhibit tumor growth and angiogenesis. Mol Cancer Ther; 12(5); 598–609. ©2013 AACR.

Introduction

Colorectal cancer is a second leading cause of adult cancer-related death in the United States and is associated with a high mortality rate (1). The lifetime risk of developing colorectal cancer in both men and women is about 1 in 20 (5.1%; ref. 2). The American Cancer Society estimated 103,170 new cases (49,920 men and 53,250 women) would be diagnosed with colon cancer during 2012 (1, 3). Screening for colon cancer can be done by colonoscopy to find polyps, and removing these polyps at an early stage can prevent cancer progression. When the polyps are allowed to persist in the colon for a long time, they may develop into cancer. Chemotherapeutic compounds currently being used for the treatment of colorectal cancer include 5-flourouracil, oxaliplatin, and irinotecan (4). Because conventional therapies, including surgical resection, chemotherapy, and radiation, are often inadequate in treating this disease, new treatment options are critically needed. Despite the emergence of novel targeted agents and the use of various therapeutic combinations, no treatment options are available that are curative in patients with advanced cancer. The magnitude of this problem mandates the need for novel therapeutic agents.

Tandutinib (Fig. 1A) is a potent FLT3 antagonist of the piperazinyl quinazoline class that can also inhibit the activation of other class III receptor tyrosine kinases platelet-derived growth factor receptor (PDGFR) and c-Kit (5). However, it does not have significant suppressive activity against a wide range of other kinases (5). By blocking FLT3 activation, tandutinib suppresses the phosphorylation of Akt and Erk2 mitogen-activated protein kinase (MAPK) pathways thereby leading to induction of apoptosis in FLT3-ITD–positive human acute myelogenous leukemia (AML) cell lines (5). Preclinical studies have shown that tandutinib is orally bioavailable, has a suitable pharmacokinetic and toxicity profile for clinical use, and is efficacious in murine models of FLT3-ITD–mediated disease (5, 6). In addition, tandutinib also inhibits the receptor for macrophage colony-stimulating factor, thereby affecting osteoclastogenesis and macrophage colony formation in vitro (7). Moreover, a recent study showed that tandutinib inhibits PDGFR-A activation resulting in reduced tumor cell growth and increased apoptosis in vitro in a sonic hedgehog–driven medulloblastoma mouse model (8). As c-Kit expression is upregulated in colon cancers (9), we considered that tandutinib might be a novel therapeutic agent for the disease.
The c-Kit proto-oncogene encodes a transmembrane tyrosine kinase receptor. Aberrant c-Kit expression, described in subgroups of patients with colorectal cancer, correlates with dismal prognosis (10, 11). c-Kit mRNA expression has been detected in various human colonic adenocarcinoma cell lines (9, 12). Furthermore, activating mutations of c-Kit protects human colon adenocarcinoma cells against apoptosis and enhance their invasive potential (12). The c-Kit ligand stem cell factor (SCF) has been also detected in normal intestinal epithelial cells (13), suggesting autocrine and paracrine control of transforming functions by SCF in human colon cancer (9). Therefore, c-Kit is a therapeutic target for colorectal carcinoma.

Upon binding with its ligand SCF, c-Kit undergoes dimerization and autophosphorylation at specific tyrosine residues Tyr567 and Tyr719. This activated receptor then phosphorylates various signaling pathways: the phosphoinositide 3-kinase 3-kinase (PI3K)/Akt/mTOR/p70S6 kinase (p70S6K), Ras/mitogen-activated protein kinase kinase (MEK)/MAPK, the Janus kinase (JAK)/STAT, and the Src signaling pathways (14). Activation of these pathways results in cellular transformation and differentiation through including proliferation, survival, adhesion, and chemotaxis (9). There is a positive feedback loop in that c-Kit can in turn be activated by the PI3K and MAPK pathway.

The PI3K/Akt/mTOR signaling axis plays a critical role in the proliferation, resistance to apoptosis, angiogenesis, and metastasis that is central to the development and maintenance of colorectal cancers (15). PI3K is activated upon growth factors binding to their cognate receptors. Activated PI3K leads to the activation of Akt by phosphorylation at Ser473 and Thr308 (16). Akt activates several downstream targets including mTOR. Deregulation of mTOR signaling occurs in several human tumors including colon cancer (15). mTOR associates with Raptor (mTORC1 complex) to phosphorylate p70S6K, which in turn phosphorylates 4E-BP1, leading to increased cell proliferation (17). In addition, mTOR associates with Rictor (mTORC2 complex) and functions in a feedback loop to phosphorylate and activate Akt at Ser473 (16).

In this article, we are the first to show the effect of tandutinib on colon cancer cells and have identified at least one mechanism of action to be through the inhibition of the Akt/mTOR signaling pathway.

Materials and Methods

Cells and reagents

HCT-116, HT-29, and SW480 human cancer cells (all obtained from American Type Culture Collection, at passage 4) were grown in Dulbecco’s Modified Eagle’s Media (DMEM) containing 10% heat-inactivated FBS (Sigma-Aldrich) and 1% antibiotic–antimycotic solution (Mediatech Inc.) at 37°C in a humidified atmosphere of 5% CO2. All the cell lines used in this study were within 20 passages after receipt or resuscitation (~3 months of noncontinuous culturing). The cell lines were not authenticated as they came from national repositories. Tandutinib was purchased from LKT Laboratories.

Proliferation and apoptosis assays

Cells were seeded on to 96-well plates and grown overnight. Then, the cells were treated with increasing doses of tandutinib (0–50 μmol/L) in 10% FBS containing DMEM. The cell proliferation was analyzed by hexosaminidase assay as described previously (18). For apoptosis, caspase-3/7 activity was measured using the Apo-one Homogeneous Caspase-3/7 Assay Kit (Promega).

Colony formation assay

Briefly, 6-well dishes were seeded with 500 viable cells per well, treated with tandutinib (25 μmol/L) in 10% FBS containing DMEM for 48 hours, the tandutinib-containing medium was removed, and the cells were incubated for an additional 10 days. Treatments were conducted in triplicate. The colonies obtained were fixed in formalin and stained with crystal violet. The colonies were compared with untreated cells.

Cell-cycle analyses

Cells were treated with tandutinib for 24- and 48-hours and subsequently trypsinized and suspended in PBS. Single-cell suspensions were fixed using 70% ethanol for 2 hours and subsequently permeabilized with PBS containing 1 mg/mL propidium iodide (Sigma-Aldrich), 0.1% Triton X-100 (Sigma-Aldrich), and 2 μg DNase-free RNase (Sigma-Aldrich) at room temperature. Flow cytometry was done with a FACS Calibur analyzer (Becton Dickinson) capturing 10,000 events for each sample. Histograms were analyzed for cell-cycle compartments, and the percentage of cells at each phase of the cell cycle was calculated using CellQuest (Becton Dickinson) analysis software.

Real time reverse-transcription PCR analysis

Total RNA isolated from HCT-116 cells treated with Trizol reagent and reverse-transcribed with Superscript II reverse transcriptase in the presence of random hexanucleotide primers (Invitrogen). cDNAs were then used for real-time PCR using Jumpstart Taq DNA polymerase (Sigma-Aldrich) and SYBR Green Nucleic Acid Stain (Molecular Probes). Crossing threshold values for individual genes were normalized to β-actin. Changes in mRNA expression were expressed as fold change relative to control. Primers used in this study were as follows: β-actin: 5′-GCTGATCCACATCTGCTGG-3′ and 5′-ATCATTGCTCTCCTCAGCG-3′; COX-2: 5′-GAATCATTCCAGCAGGAATTTG-3′ and 5′-TCCTGACT-GGCGTGGACA-3′; VEGF: 5′-AGGCAGAAGAA-TCCCGGTA-3′ and 5′-TGCTTCTCCGTGTCGAC-3′; insulin, 0.005 mg/mL transferrin, 100 ng/mL hydrocortisone, 10% FBS (Sigma-Aldrich), and 1% antibiotic–antimycotic solution (Mediatech Inc.) at 37°C in a humidified atmosphere of 5% CO2. All the cell lines used in this study were within 20 passages after receipt or resuscitation (~3 months of noncontinuous culturing). The cell lines were not authenticated as they came from national repositories. Tandutinib was purchased from LKT Laboratories.
interleukin (IL-8: 5'TCTCTGCGAGCTTCTGTATT-3' and 5'\-TATGCACTGACATCTAAGTCTCTTACGA-3'; cyclin D1: 5'\-AATGACCCAGCAGATTTCTC-3' and 5'\-TCAGTTCAAGCTTTGCAGC-3'; and c-Myc: 5'\-CACACATCGACACAATACTAGCA-3', and 5'\-TGAGCCCTCTTGGCACAGC-3'.

Western blot analysis

Cell lysates were subjected to PAGE and blotted onto Immobilon polyvinylidene difluoride membranes (Millipore). Antibodies were purchased from Cell Signaling Technology and Santa Cruz Biotechnology. The following are the catalog numbers for antibodies from Cell Signaling Technology: caspase-3-9662S, Bcl2-2876S, Bcl-XL-2764S, caspase-8/9-9725S, caspase-3/7-2974S, mTOR-2972S, phospho-p70S6K-9208S, phospho-Akt (Thr308)-9275S, Akt-9272S, phospho-COX-2-4842S, caspase-3-9662S, Bcl2-2876S, Bcl-XL-2764S. The following antibodies were purchased from Cell Signaling Technology and Santa Cruz Biotechnology. The following are the catalog numbers for antibodies from Santa Cruz Biotechnology: VEGF-sc-152, IL-8-sc-7922, caspase-3-9662S, Bcl2-2876S, Bcl-XL-2764S.

Plasmids and transfections

HCT-116 and SW480 cells were transfected with plasmid 9008: 1036 pcDNA3 Myr-HA-Akt1 or the empty vector pcDNA3 (Addgene Inc.) and subsequently treated with 25\-mol/L tandutinib for 48 hours and conducted Western blot analysis. Cell proliferation and apoptosis were detected by hexoaminadase and the Apo-ONE fluorescent substrate. The activity was observed within 48 hours in all 3 cell lines such as caspase-8 or caspase-9 (19).

Results

Tandutinib induces apoptosis

Given the effects of tandutinib on suppression of proliferation and colony formation, we next determined whether the compound affects cell-cycle progression. After 24 hours of tandutinib treatment, there was a significantly higher number of cells arrested in the G2-M phase (Fig. 2A). In addition, there was a greater number of dead cells in both HCT-116 and SW480 cell lines (Fig. 2A). At 48 hours, while tandutinib induced G0–G1 arrest in HCT-116 cells, there was G2-M arrest in SW480 cells. We also determined how the cells died following tandutinib treatment. Caspases are a family of proteins known for the execution of apoptosis. Caspase-3, 7, and 8 are key effector molecules of apoptosis in a variety of cancer cells that amplify signals from initiator caspases, such as caspase-8 or caspase-9 (19). Increased caspase-3, 7 activity was observed within 48 hours in all 3 cell lines HCT-116, SW480, and HT-29 treated with tandutinib. Finally, the slides were counterstained with hematoxylin and mounted. The slides were examined in Nikon Eclipse Ti microscope under a ×40 objective.

Statistical analysis

All values are expressed as the mean ± SEM. Data were analyzed using an unpaired 2-tailed t test. P < 0.05 was considered statistically significant.
genes Bcl2 and Bcl-XL proteins while increasing the expression of apoptosis-promoting Bax protein (Fig. 2D). Moreover, we have also determined the effect of tandutinib on caspase-3/7 activity in FHC normal colonic epithelial cells. There was no significant increase in caspase-3/7 activity in normal colonic epithelial treated with 25 μmol/L of tandutinib (data not shown). These data suggest that tandutinib is a potent inducer of apoptosis of colon cancer cells.

**Tandutinib affects expression of cell-cycle–related proteins**

To further characterize the mechanism of cell death, we examined the level of expression of several known cell-cycle regulatory factors (20). Cyclin D1 overexpression has been linked to the development and progression of cancer (21). It is a cell-cycle regulatory protein that regulates the G1 to S-phase transition of the cell cycle and functions as a cofactor for several transcription factors. Consistent with cell-cycle arrest, the expression of cyclin D1 was decreased at both the mRNA and protein levels in the 2 cell lines (Fig. 3A and B). Furthermore, cyclin A1 and B1 also reduced following tandutinib treatment in both HCT-116 and SW480 cells (Fig. 3B). In addition, c-Myc is upregulated in cancers. In both HCT-116 and SW480 cells, tandutinib treatment resulted in reduced levels of c-Myc expression (Fig. 3A and B).
Tandutinib inhibits expression of cancer-promoting genes

COX-2, a key rate-limiting enzyme in prostaglandin synthesis, is overexpressed in many cancers. Previous studies have shown increased COX-2 levels in colorectal cancer (22, 23). COX-2 plays a significant role in increased invasiveness, promotion of angiogenesis, and resistance to apoptosis (24). Therefore, we next determined the effect of tandutinib on COX-2 expression. Tandutinib reduced COX-2 mRNA and protein levels in both HCT-116 and SW480 cells (Fig. 3C and D). Prostaglandins and the other tumor promoters are known to induce the expression of VEGF and IL-8 in epithelial cells, thereby promoting angiogenesis and hence tumor growth (25). VEGF and IL-8 are known potent inducers of capillary growth into the tumor, and without angiogenesis, tumor growth normally stops at a diameter of about 1 to 2 mm (26). Hence, we also determined the effect of tandutinib on the expression of these 2 genes. Both VEGF mRNA and IL-8 protein expression were significantly reduced in both HCT-116 and SW480 cells (Fig. 3C and D). Similar results were obtained in HT-29 cells (data not shown).

Tandutinib affects c-Kit and Akt/mTOR signaling

Tandutinib is a known inhibitor of PDGFR and c-Kit in AML cells lines (5). Aberrant activation of c-Kit protects colon carcinoma cells from apoptosis and enhances their invasive potential (12). To further show the effect of tandutinib on c-Kit in colon cancer cells, a Western blot analysis was conducted. Tandutinib treatment significantly downregulated the phosphorylation of c-Kit in both HCT-116 and SW480 cells (Fig. 4A). Similar result was obtained in HT29 cells (data not shown). Previous studies have shown that tandutinib selectively blocks
FLT3-ITD phosphorylation, leading to an inhibition of Akt and Erk signaling and to induction of apoptosis in FLT3-ITD–positive human AML cell lines (5). To determine whether a similar mechanism was occurring in colon cancer cells, we determined the effect of tandutinib on the Akt/mTOR pathway. Western blot analyses showed that tandutinib treatment downregulated the phosphorylation of both Akt and mTOR in the 2 cell lines (Fig. 4B). Furthermore, tandutinib also further downregulated the phosphorylation of downstream target protein P70S6K and 4EBP1 (Fig. 4B). In addition, tandutinib treatment increased PTEN expression in both HCT-116 and SW480 cells. We also determined the effect of tandutinib on Akt phosphorylation in normal colonic epithelial cells. There was no significant difference observed in the phosphorylation of Akt in normal FHC cells (data not shown).

We next determined the effect of overexpressing a constitutively active form of Akt on tandutinib-mediated cell growth. We overexpressed myristoylated Akt in the 2 cell lines, HCT-116 and SW480, and subsequently treated the cells with tandutinib. As before, in control cells, tandutinib treatment significantly suppressed cell proliferation. However, this tandutinib-mediated suppression was reduced in the presence of myristoylated Akt (Fig. 4C, right). We confirmed this by determining the levels of apoptosis by caspase-3/7 assay. While tandutinib alone increased caspase-3/7 activity, this was significantly reduced in cells expressing constitutively active Akt in both HCT-116 and SW480 cells (Fig. 4C, left). Additional confirmation was obtained by Western blot analyses. Expression of constitutively active Akt resulted in increased expression of Bcl2 and reduced expression of Bax proteins, even in the presence of tandutinib in the 2 cell lines (Fig. 4D, right). These data suggest that tandutinib-mediated suppression of cell growth occurs, in part, through suppression of Akt phosphorylation.

**Tandutinib inhibits colon tumor xenograft growth and angiogenesis**

To evaluate the role of tandutinib on tumor growth in vivo, we next examined its effects on HCT-116 colon cancer cell xenografts. HCT-116 were injected into the flanks of athymic nude mice and allowed to develop into a xenograft. One week following injection of the cells, tandutinib mixed with 5% sodium bicarbonate was administered intraperitoneally daily for 3 weeks. Tandutinib inhibited the growth of the tumor xenografts (Fig. 5C). The excised tumors from control animals weighed about 1,200 mg, whereas those treated with tandutinib weighed about 400 mg (Fig. 5B, top and bottom). In addition, tumor volume was significantly decreased (Fig. 5C). There was no apparent change in liver, spleen, or body weight in the animals (data not shown). These data imply that the tandutinib is a potential therapeutic agent for treating colon cancers. We also determined the effect of the compound on tumor vascularization by staining for endothelial-specific antigen CD31. As shown in Fig. 5D, the treatment with the tandutinib leads to a significant reduction in CD31 staining and to the obliteration of the normal vasculature (Fig. 5D).

**Tandutinib inhibits the expression of cancer-promoting genes and Akt/mTOR signaling proteins in tumor xenograft tissues**

Given that tandutinib inhibits cancer-promoting genes COX-2 and VEGF in colon cancer cells and reduced microvasculature within the xenograft tumors, we
investigated whether the treatment affects the COX-2 and VEGF in the tissues. Western blot analyses showed that the tandutinib significantly reduced the expression of COX-2 and VEGF when compared with controls in the tumor xenograft tissues (Fig. 6A). Cyclin D1 protein levels were also significantly lower in tandutinib-treated tumor xenografts (Fig. 6A). These data were confirmed by immunohistochemical analyses (Fig. 6C, left). We also quantified the number of cells expressing COX-2, VEGF, and cyclin D1 in the immunohistochemistry and found all 3 proteins to be significantly decreased following tandutinib treatment (Fig. 6D, left). These data suggest that tandutinib affects cancer-promoting genes in vivo.

We also examined the effects on Akt/mTOR signaling proteins in the tumor tissues obtained from control and tandutinib-treated mice. Treatment with tandutinib again resulted in significantly lower levels of phosphorylation of Akt, mTOR, p70S6K, and 4E-BP1 than control untreated tumors (Fig. 6B). Again, further confirmation of the downregulation was obtained by
immunohistochemistry for the proteins in the xenograft tissues (Fig. 6C, middle and right). We also determined the number of cells expressing phospho-Akt, phospho-mTOR, phospho-P70S6K, and phospho-4EBP1 in the tumor sections and found them to be significantly decreased following tandutinib treatment (Fig. 6D, right). These data suggest that tandutinib significantly affects expression of Akt/mTOR signaling–related proteins, which might contribute to the inhibitory effects of this treatment.

**Discussion**

Given the high mortality rate due to colon cancer and the significant morbidity, apparent toxicity and poor response rates of current chemotherapy regimens there has been a big push to identify novel therapeutic modalities that have fewer toxicity profiles. The PI3K/Akt/mTOR signaling axis plays a critical role in the proliferation, resistance to apoptosis, angiogenesis, and metastasis that is central to the development and maintenance of colorectal cancer cells (27–29). Therefore, therapeutic targeting of the PI3K pathway with its downstream targets Akt and mTOR at multiple molecular levels may provide better antitumor effects than selective inhibition of only one component of the pathway. Our results indicate that tandutinib possesses potential as a promising therapeutic agent against colon cancer.

Previous studies showed that c-kit overexpression in patients with colorectal cancer resulted in poor prognosis (10, 11). c-Kit plays an important role in cell growth differentiation, motility, and cell survival in a variety of cancers including colorectal cancer (9). Furthermore, c-kit protects the cells from undergoing apoptosis while also increasing their invasiveness in colon cancer cells (12). In fact, the c-kit tyrosine kinase inhibitor STI571 significantly inhibits cells survival and invasive potential of these cells and hence may be appropriate for colorectal cancer therapy (9, 30). Another study also reported that BAY43-9006 inhibits c-Kit, along with several receptor tyrosine kinases. Moreover, BAY43-9006 inhibits tumor growth,
angiogenesis, and MAPK pathway in colon, pancreatic, and breast tumor cell lines, in part, through inhibiting the expression of VEGFR-2 and -3 (31). In addition, c-Kit receptor signaling enhanced the proliferation and invasion of colorectal cancer cells through the PI3K/Akt pathway (32). Similar to these studies, tandutinib treatment effectively downregulated the c-kit phosphorylation in colon cancer cells. Moreover, tandutinib inhibited cell proliferation and induced apoptosis in colon cancer cells, in part, through inhibiting PI3K/Akt signaling.

Aberrant PI3K/Akt signaling is common in colon cancer. Recent studies have reported the potential for therapeutic targeting of the PI3K/Akt/mTOR network at multiple molecular levels (33, 34). mTOR resides in 2 distinct multiprotein complexes called mTORC1 and mTORC2 (35). mTORC1 directly phosphorylates ribosomal protein S6 kinase 1 (S6K1) and the eukaryotic translation initiation factor eIF4E-binding protein 1 (4EBP1), both involved in protein translation (36, 37). Moreover, mTORC2 can phosphorylate Akt on Ser 473, thereby leading to activation of the Akt pathway and thus several cancer-related cellular responses, including increased cell growth, proliferation, and survival (38). A recent preclinical study with OSI-027, a potent inhibitor of Akt/mTOR suppressed the growth of colon cancer (39). In addition, Akt and mTOR inhibitors can downregulate leptin-mediated PI3K/Akt/mTOR signaling affecting colon cancer cell proliferation and inducing apoptosis (40). Our studies in the manuscript had
similar results with tandutinib effectively downregulating phosphorylation of both Akt and mTOR phosphorylation and also mTOR downstream target proteins phospho-p70S6K (Thr389) and phospho-4EBP1 (Thr37/46). These findings suggest that tandutinib downregulates the functions of Akt and mTOR. Moreover, tandutinib inhibited proliferation and induced apoptosis in colon cancer cell lines and suppressed formation of microvessels in the xenografts indicating that the in vivo antiancrosis effects of tandutinib may be due to induction of apoptosis, in addition it also inhibits angiogenesis.

In our in vivo studies, we observed marked decrease in tumor xenograft growth in mice treated with tandutinib. Moreover, there was no apparent toxicity observed in liver, kidney, and spleen. A significant body of evidence suggest that constitutive COX-2 expression is a contributing factor for promoting colorectal cancer (41). In addition, there are various genetic, epigenetic, and inflammatory pathways involved in the etiology and development of colorectal cancer (41). Tandutinib treatment seems to mediate its actions through multiple molecular targets including COX-2. Given the high levels of resistance to apoptosis due to COX-2 overexpression (42, 43), treating cells with tandutinib could potentially restore apoptotic susceptibility of colon cancer cells, in part, through the downregulation of this gene.

Recent studies showed that IL-8 and its receptors are significantly upregulated in the tumor and act as key regulators of proliferation, angiogenesis, and metastasis. Although IL-8 overexpression has been correlated with the inflammation-related risk of sporadic colorectal cancer (44), it is also a potent inducer of proliferation of colorectal cancer cells (45). Hence, IL-8 has been considered a therapeutic target (46). In this regard, the IL-8 receptor antagonist SCH-527123 was shown to inhibit tumor growth and sensitize cells to oxaliplatin in preclinical colorectal cancer models (47). Tandutinib treatment inhibits IL-8 expression, but it remains to be seen if this inhibition also correlates with changes in inflammatory responses that are associated with the development of cancer.

VEGF and its receptors are overexpressed in colon cancer and play an important in angiogenesis and promotion of tumor growth (48, 49). Pharmacologic inhibition with STI571 (Gleevec) of VEGF expression also suppresses VEGF- and basic fibroblast growth factor (bFGF)-induced angiogenesis in vivo (50). The compound also inhibits angiogenesis and tumor growth in an experimental bone metastasis model (50). Our studies with tandutinib significantly downregulating VEGF expression in both in vitro and in vivo tumor tissues suggest that tandutinib can also affect angiogenesis. Future studies are warranted to determine whether the combination of tandutinib with known angiogenesis inhibitors such as STI571 has greater effect than either compound alone.

In conclusion, our studies show that treatment of colon cancer cells with tandutinib results in significant inhibition of tumor cell growth, both in vitro and in vivo. Our studies show that tandutinib affects Akt/mTOR and c-kit pathways. One of the biggest problems with therapeutic compounds is the toxicity to normal cells. One mechanism to reduce toxicity is to use a combination of compounds that have synergistic activity. Hence, identifying a compound or compounds can act synergistically with tandutinib may have value in reducing toxicity associated with the amount of compound needed to have therapeutic efficacy. Nevertheless, in our studies, we observed that tandutinib does not affect proliferation of normal colonic epithelial cells, strongly suggesting that the compound has promising potential for use as a therapeutic option for colon cancer.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Disclaimer
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Authors’ Contributions
Conception and design: D. Subramaniam
Development of methodology: S. Ponnurangam, P. Rangarajan, D. Subramaniam
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): D. Standing, D. Subramaniam
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): S. Ponnurangam, P. Rangarajan, D. Subramaniam
Writing, review, and/or revision of the manuscript: D. Subramaniam
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): S. Ponnurangam
Study supervision: D. Subramaniam

Acknowledgments
The authors thank Dr. Shrikant Anant for supporting the studies and with helpful suggestions and for critically reading the manuscript. They also thank members of Dr. Shrikant Anant’s laboratory and the cancer center for their discussion during the course of this study.

Grant Support
This work was supported by Thomas O’Sullivan Foundation and a pilot grant from the NCI-designated University of Kansas Caner Center (P30CA168524-01; D. Subramaniam) and the Flow Cytometry Core Laboratory, which is sponsored, in part, by the Cancer Center.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received September 14, 2012; revised January 29, 2013; accepted February 8, 2013; published OnlineFirst February 20, 2013.

References


Molecular Cancer Therapeutics

Tandutinib Inhibits the Akt/mTOR Signaling Pathway to Inhibit Colon Cancer Growth

Sivapriya Ponnurangam, David Standing, Parthasarathy Rangarajan, et al.


Updated version Access the most recent version of this article at:
doi:10.1158/1535-7163.MCT-12-0907

Cited articles This article cites 49 articles, 12 of which you can access for free at:
http://mct.aacrjournals.org/content/12/5/598.full.html#ref-list-1

Citing articles This article has been cited by 1 HighWire-hosted articles. Access the articles at:
/content/12/5/598.full.html#related-urls

E-mail alerts Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.